Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/7/2018
SIETES contiene 92427 citas

 
 
 1 a 20 de 28 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: a retrospective cohort study. Br J Clin Pharmacol 2017;84:1. [Ref.ID 102184]
3. Cita con resumen
6. Cita con resumen
Anónimo. Ponatinib. Prescrire 2015;35:176-81. [Ref.ID 98925]
7. Cita con resumen
8. Cita con resumen
McCurry J. Former Novartis employee arrested over valsartan data. Lancet 2014;383:2111. [Ref.ID 97775]
9. Cita con resumen
Anónimo. Bosutinib. Prescrire 2014;34:10. [Ref.ID 97006]
10.Tiene citas relacionadas
Doroshow JH. Overcoming resistance to targeted anticancer drugs. N Engl J Med 2013;369:1852-3. [Ref.ID 96519]
11.Tiene citas relacionadas
Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Godlman JM, Shah NP, Kantarjian H, PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013;369:1783-96. [Ref.ID 96515]
12.Tiene citas relacionadas Cita con resumen
Groarke JD, Cheng S, Moslehi J. Cancer-drug discovery and cadiovascular surveillance. N Engl J Med 2013;369:1779-81. [Ref.ID 96514]
13. Cita con resumen
Anónimo. Nilotinib: effets indésirables cardiovasculaires. Prescrire 2013;33:667. [Ref.ID 96187]
14. Cita con resumen
Shah R, Morganroth J, Shah DR. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf 2013;36:491-503. [Ref.ID 95770]
15.
Shah DR, Shah RR, Morganroth J. Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy. Drug Saf 2013;36:413-26. [Ref.ID 95664]
16.
Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf 2013;36:295-316. [Ref.ID 95517]
17. Cita con resumen
Pirmohamed M. Drug-grapefruit juice interactions. BMJ 2013;346:9. [Ref.ID 94758]
18. Cita con resumen
Wise J. NICE backs leukaemia drug after company drops price. BMJ 2012;344:5. [Ref.ID 92654]
19. Cita con resumen
Anónimo. Dasatinib: hypertension artérielle pulmonaire. Prescrire 2011;31:429. [Ref.ID 91049]
20.Tiene citas relacionadas
Sawyers CL. Even better kinase inhibitors for chronic myeloid leukemia. N Engl J Med 2010;362:2314-5. [Ref.ID 88995]
Seleccionar todas
 
 1 a 20 de 28 siguiente >>